RFP, CGN and CGA Opportunities
The Alliance is a community dedicated to connecting healthcare education professionals to promote best practices that improve patient care. To help achieve this, we collect information on research proposals and grants offered through other healthcare-related organizations. If your company is interested in posting a request for grant applications, please contact the Alliance Business Office at firstname.lastname@example.org.
Alnylam is committed to supporting global healthcare improvement for patients through the medical and scientific understanding of our therapeutic areas of interest for healthcare professionals. Alnylam is currently accepting submissions in response to the following Requests for Proposals (RFPs).
Proposals must be submitted at https://alnylam-grants.steeprockinc.com
Questions regarding this RFP may be sent to email@example.com
- Identifying and Evaluating Patients at High Risk of Monogenic Kidney Stone Disorders including Primary Hyperoxaluria Type 1 (PH1)
- Submission Deadline: August 14, 2020
- Details about this RFP may be found at:
**UPDATED RFE** (6/26/2020)
Amicus Therapeutics is committed to supporting high quality independent medical education (IME) that narrows unmet educational needs and improves healthcare provider knowledge, competence, and performance. IME supported by Amicus is intended to ultimately improve the outcomes of patients with rare and orphan diseases.
Amicus is posting a Request for Education (RFE) to inform qualified medical education providers that we are currently accepting requests for the following:
Therapeutic Area: Fabry disease
Program Type: Satellite Symposium at ACMG 2021
Submission Deadline: July 17, 2020
Please visit our website at Amicus Global Medical Affairs to learn more details.
Astellas, US Independent Medical Education and Pfizer Call for Independent Medical Education Grant Applications in Oncology – Prostate Cancer. Application Deadline: February 27, 2020.
Astellas, US Independent Medical Education and Seattle Genetics Call for Independent Medical Education Grant Applications in Oncology – Urothelial Carcinoma (UC). Application Deadline: February 24, 2020.
Bristol-Myers Squibb accepts funding requests within the following therapeutic areas of interest. As areas of interest and funding consideration may change periodically, please consult this website frequently. Please note that international funding opportunities may differ.
- Genetically Defined / Rare Diseases
Colorectal Cancer Alliance
Each year the Colorectal Cancer Alliance’s Chris4Life Research Program funds colorectal cancer investigator-initiated grants as part of our mission to end this disease in our lifetime.
This year the Chris4Life program will fund three three-year grants in the amount of $300,000 each will be awarded to support the work of the researcher while working on young-onset colorectal cancer research. Additionally, one two-year grant in the amount of $200,000 will be awarded to support the work of the researcher while studying health disparities in colorectal cancer. Applications should address one of the following: risk factors, prevention, biological mechanisms, host/environment interactions at the individual or population level. If your research falls within the scope of this grant, please apply or share this information with your colleagues.
To be considered, Principal Investigators must have a Ph.D., MD, MD/Ph.D. or equivalent degree, and be research staff or a faculty member at a non-profit US academic or research institution at the level of an Assistant Professor (or its equivalent) or higher.
Applications must adhere to the Alliance research guidelines. More details on the research areas and specific guidelines can be found on our website: https://www.ccalliance.org/funding-research.
Application submission deadline: March 16, 2020 (11:59 pm EST)
Award announcement: Summer 2020
If you have any questions, please contact us at firstname.lastname@example.org or 202-688-0156
- General oncology, common and/or rare solid tumors
- Virtual, digitally interactive certified program that meets (not adds to) the overwhelming demands of clinicians in the frontlines of care during COVID-19
- U.S. academic and community medical oncologists, pathologists, oncology nurses, pharmacists, and other clinical oncology team members
All submissions will be reviewed in compliance with our Standard Operating Procedures and policies, impartially without any preset grant decision(s) made at the release of this RFP.
Questions regarding this RFP can be submitted to OGE-CME@dsi.com
Genentech is seeking to support learning initiatives that demonstrate a strategy that evolves knowledge-based medical education into a “healthcare Improvement” initiative that accelerates the awareness and application of evidence-based medicine, resulting in appropriate care for patients and relevant, measurable, clinical outcomes.
Therapeutic area(s) of interest:
- Non-Malignant Blood Disorders
Genentech is posting a Call for Grants (CGN) in support of IME activities in Early Non-Small Cell Lung Cancer.
Genentech is posting a Call for Grants (CGN) in support of IME activities for Stroke.
Genentech is posting a Call for Grants (CGN) in support of IME activities on March 16, 2020, in Hepatocellular Carcinoma.
Genentech is posting a Call for Grant Notification (CGN) for Prostate Cancer in support of IME activities.
With increasing complications from COVID-19, we are extending the deadlines associated with the Call for Grant Notification (CGN) in support of education in hepatocellular carcinoma for Hepatologists.
Genentech is posting a Call for Grant Notification (CGN) for Disparities in Care (in TNBC, HCC, and general oncology) in support of IME activities.
Genentech is posting a Call for Grant Notification (CGN) on June 8, 2020 for General Oncology in support of IME activities.
Genentech is posting a Call for Grant Notification (CGN) on June 12, 2020 for Hemophilia A and Acute Myeloid Leukemia (AML) in support of IME activities.
Indivior supports independent medical education activities that provide for an increased understanding of scientific, clinical, or healthcare issues related to the company’s therapeutic areas of interest.
Therapeutic areas of interest:
- Opioid Use Disorder
To view open RFPs and complete details regarding grant submission, please visit the following site on a regular basis: grants.indivior.com
Insmed has funding to support independent accredited education intended to improve clinician knowledge, competence, and performance in the diagnosis and treatment of patients with Nontuberculous Mycobacterial (NTM) Lung Disease. Please refer to www.insmed.com/grants-giving/ for grant submission requirements. For additional questions about the CGA process please contact Insmed Medical Education at email@example.com. Grant submissions should align to the specifications in the downloadable CGA.
Therapeutic Areas: Pulmonology/Infectious Disease
Nontuberculous Mycobacterial (NTM) Lung Disease
Focus Area: Education Activities associated with 2020 CHEST and IDWeek and other Medical Society Conferences
Submission Deadline: December 1, 2019
Medicare Access and CHIP Reauthorization Act of 2015 (MACRA)
The Centers for Medicare & Medicaid Services (CMS) recognizes the benefits of measure development by external stakeholders with specific knowledge of clinician and patient perspectives and needs, such as clinical specialty societies, clinical professional organizations, patient advocacy organizations, educational institutions, independent research organizations, health systems, and other entities.
On March 2, 2018, CMS published the “Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) Funding Opportunity: Measure Development for the Quality Payment Program” on Grants.gov. The purpose of this Funding Opportunity is to provide technical and funding assistance in the form of cooperative agreements to entities to develop, improve, update, or expand quality measures for use in the Quality Payment Program (QPP).
For more information and to see the ‘Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) Funding Opportunity: Measure Development for the Quality Payment Program’ search by the title or the Catalog of Federal Domestic Assistance (CFDA) number, 93.986 on Grants.gov.
Novo Nordisk Inc.
Novo Nordisk is committed to supporting independent medical education programs that meet the educational needs of health care professionals (HCPs), patients and the community in ways that measurably grow their knowledge and skills to optimize patient or self care in the following therapeutic areas of interest:
Please visit www.novonordiskgrants.com to apply for educational grants and access the IME Funding Document that provides information about educational priorities and available funding as well as current Request for Proposals (RFPs)/Call for Concept Proposals (CCPs) within these therapeutic areas.
Pfizer Independent Grants for Learning & Change (IGLC)
The mission of Pfizer Independent Grants for Learning & Change is to partner with the global healthcare community to improve patient outcomes in areas of mutual interest through support of measurable learning and change strategies. The Joint Commission is an independent, not-for-profit organization that accredits and certifies nearly 21,000 health care organizations and programs in the United States.
To view open RFPs and complete details, please visit this webpage.
The Regeneron and Sanofi Genzyme Alliance seeks to close important medical educational gaps with regard to Advanced Basal Cell Carcinoma (BCC) through consideration of grant proposals for 2020-2021 independent medical education activities. Target audiences include Dermato-Oncologist, Oncologists, Dermatologists, Mohs surgeons (US Only), Pharmacists, Registered Nurses, and advanced-level practitioners via live and enduring distribution channels; please refer to the Request for Proposal for further details.
Shionogi accepts funding requests within the following therapeutic areas of interest.
- Gram-negative multidrug-resistant infectious disease (ID)
- Thrombocytopenia associated with chronic liver disease (CLD)
- Opioid-induced Constipation (OIC)
The call for grants (CFG) opportunities will change on a quarterly basis. Please consult our website to identify current opportunities.
TRC Healthcare (TRC), the creators of Pharmacist’s Letter, is committed to helping clinicians and healthcare professionals make safe, effective, and efficient medication decisions. In support of this mission, TRC is currently accepting submissions in response to the following Requests for Proposals (RFPs).
- Antimicrobial Stewardship for Hospital Pharmacists
- Opioid Stewardship for Hospital Pharmacists
- Acute Care Anticoagulation Management for Hospital Pharmacists
Proposals may be submitted by individuals or groups and are due December 13, 2019. Please see the individual RFPs for more details.
To learn more about TRC, please visit https://trchealthcare.com/about-us/.
UCB, Inc., is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
Here are the following open RFPs:
UCB.PsO1.Feb2020 – Psoriatic Disease: Improving Knowledge on Current Impact and Advancements in Disease Management
UCB.PsO2.Feb2020 – Psoriatic Disease: Improving Knowledge on Current Impact and Advancements in Disease Management for Payers and Healthcare Decision Makers
UCB.PsO3.Feb2020 – Psoriatic Disease: Improving Knowledge on Current Impact and Advancements in Disease Management for Nurse Practitioners and Physician Assistants